SIGA Reports $88M TPOXX Revenue, $24M Pre-tax Income, $13M Asia Order
In 2025, SIGA generated $88 million in TPOXX product revenues and achieved $24 million in pre-tax operating income while securing $27 million in additional U.S. government funding. In January 2026, the company booked a $13 million Asia Pacific procurement order for oral TPOXX under a new multi-year contract.
1. Full-Year 2025 Financial Results
SIGA posted $88 million in TPOXX product sales in 2025, contributing to total revenues of $94.6 million versus $138.7 million in 2024. The company reported $23.7 million in operating income and $30.4 million in income before taxes, down from $70.0 million and $76.1 million respectively.
2. Government Funding and BARDA Contracts
During 2025, BARDA modified SIGA's 19C contract to add $27 million for pediatric development and manufacturing activities, bringing total U.S. government funding increases to $27 million. The company also received a $26 million IV TPOXX procurement order in March 2025 and secured a $13 million Asia Pacific order in January 2026 under a new multi-year contract.
3. Product Delivery Breakdown
SIGA delivered $53 million of oral TPOXX and $26 million of IV TPOXX to the U.S. Strategic National Stockpile in 2025, along with $6 million of oral product to an international customer. Fourth quarter product sales totaled $2.2 million, reflecting contract timing and product mix differences.
4. CHMP Referral and 2026 Outlook
SIGA expects the CHMP to affirm tecovirimat's smallpox, cowpox, and vaccinia indications in March 2026 and recommend withdrawal of the mpox indication based on recent trial results. The company aims to build on its government partnerships to secure additional procurement contracts as the foundation for future revenues.